Tranche Update on Union Korea Pharm Co., Ltd.'s Equity Buyback Plan announced on May 18, 2021.
June 11, 2021 at 01:03 am
Share
From May 18, 2021 to June 10, 2021, the company has repurchased 200,000 shares, representing 2.53% for KRW 3,104.7 million. With this, the company has completed the repurchase of 200,000 shares, representing 2.53% for KRW 3,104.7 million under the buyback announced on May 18, 2021.
UNION KOREA PHARM CO.LTD. is a Korea-based company mainly engaged in the manufacturing and distribution of pharmaceuticals. The Company manufactures and sells specialty medicines through formulations such as solid dosage forms, liquid injections, and cefa powder injections. Major products include antibiotics such as kepodon injection and ceftazime injection 1g for the prevention and treatment of infectious diseases; musculoskeletal drugs for treating arthritis contains unihyal injection and galithio injection; circulatory system dugs for the treatment of cerebrovascular diseases, such as cacetile tab and limasta tab; as well as drugs for digestive system such as digestive disorders. In addition, the Company engaged in the contract manufacturing operation (CMO) business for other pharmaceutical companies. The Company distributes its products within domestic market and to overseas markets including Middle East, Southeast Asia and Latin America.
UNION KOREA PHARM CO., LTD. 
